In vivo gene transfer of glutamate decarboxylase (GAD) has been explored as a means of inducing or increasing the production of the inhibitory amino-acid neurotransmitter, GABA. This strategy has been applied to neuroprotection, seizure prevention, and neuromodulation. In the present experiment, AAV2 was used to transfer the genes for green fluorescence protein (GFP) and GAD65 into the lateral nucleus of the rat hypothalamus. Microinjection of 500 nl of AAV2 resulted in transduction of a 0.2570.04 mm 3 with targeting errors of X ¼ 0.48 mm, Y ¼ 0.18 mm, Z ¼ 0.37 mm using standard stereotactic technique. Pre-and postinjection food and water consumption, urine and feces production, and weight were recorded. In comparison with rAAVCAGGFPand PBS-injected animals, rats treated with rAAVCAG-GAD65 demonstrated reduced weight gain (Po0.014) and transiently reduced daily food consumption (Po0.007) during the postoperative period. No changes in water consumption or waste production were recorded. Effective GAD65 gene transfer was confirmed with in situ hybridization using a probe to the woodchuck post-transcriptional regulatory element sequence included in the vector. These findings suggest that increased GABA production in lateral nucleus of the hypothalamus induced by GAD65 gene transfer may reduce weight gain through reduced feeding.
Introduction
In the past decade, stereotactic lesions of the human brain have been largely replaced by targeted drug delivery and neurostimulation to achieve modulation of nervous system function. Ablative pain procedures have been replaced in many cases by intrathecal narcotic pumps, while ablative spasticity procedures have been partially replaced by intrathecal baclofen pumps. Pallidotomy for the relief of Parkinsonian symptoms has been replaced by deep brain stimulation. Nonetheless, the application of mechanical prosthetics within the human nervous system has limitations. These devices are subject to a significant rate of mechanical failure and infections. In vivo gene delivery has the potential to provide an alternative means of focused neuromodulation.
By inducing the expression of genes that play a role in synaptic activity, the functional role of these neurons may be altered. The most common examples of this strategy involve the transfer of genes for precursors to neuropeptide transmitters, or for the enzymes that produce neurotransmitters. Wilson et al 1 have demonstrated that herpes simplex (HSV) vectors may be used to transfer the gene for preproenkephalin to spinal sensory neurons. Preproenkephalin gene transfer can inhibit the perception of neuropathic pain and somatic pain. 2 Many authors have pursued the transfer of genes for enzymes that produce dopamine as a means of replacing dopamine production in models of Parkinsonism. Combinations of the genes for tyrosine hydroxylase (TH), and aromatic acid decarboxylase (AADC) have successfully enhanced dopamine production and reduced the functional consequences of dopamine depletion in a variety of models. 3, 4 Finally, the transfer of the gene for glutamate decarboxylase (GAD), the rate-limiting enzyme in GABA production, has been investigated as a means of increasing inhibitory synaptic activity. Adenoviral, retroviral, and adeno-associated viral (AAV) GAD vectors have been designed with confirmed GABAergic activity in cell lines, 5 primary neuronal and glial cultures, 6, 7 and organotypic hippocampal cultures. 6 These investigators speculate that GAD vectors might act therapeutically in a variety of disorders thought to result from excess synaptic excitation, including neurodegenerative disorders and epilepsy. More recently, GAD gene transfer has been applied to focused neuromodulation in models of Parkinson's disease 8 Electrophysiological evidence suggests that subthalamic nucleus (STN) GAD65 gene transfer has the capacity to change the excitatory output of this nucleus to inhibitory output. Additionally, microdialysis confirmed that GAD65 gene transfer increased the production of GABA in the substantia nigra (SN) following STN stimulation. 9 These experiments suggest that GAD65 gene transfer represents a means of focused neural inhibition. Based on this rationale, a Phase I trial of GAD gene transfer to the human STN has recently been approved by the FDA for Parkinson's disease.
The role of the hypothalamus in control of feeding behaviors has been extensively studied. Anand and Brobek 10 documented that lesions in the lateral nucleus of the hypothalamus (LH) were capable of producing sustained reductions in body weight in rats. The reciprocal effect can be achieved through electrical stimulation of the LH. 11, 12 These findings suggest that the LH plays a role in driving feeding behavior. Controversy has persisted as to whether the neurons of the LH or axons passing through the LH are responsible for this function.
Histological studies have revealed a high concentration of GABA in a variety of hypothalamic nuclei including the LH. 13 These findings motivated an attempt to manipulate feeding behavior through the local administration of GABA antagonists. Injection of bicuculline 14 or picrotoxin 15 into the LH results in hyperphagia, suggesting that GABA receptors capable of modulating feeding behavior exist within the LH. Conversely, LH GABA injection results in reduced neuronal firing frequency, while LH GABA and muscimol (GABA agonist) injection reduces food intake. 15 These studies suggest that LH GABA receptors regulate food consumption.
In order to further test the potential of GAD65 gene transfer as a means of focused neuromodulation, the present study demonstrates that rAAVCAGGFP stereotactic microinjection can be accomplished in a precise location and defined distribution. The proximity of the LH to more medial structures that drive anorexic behaviors makes precise targeting and distribution of gene transfer requisite in order to effect focused neuromodulation. Next, the effect of stereotactic LH microinjection of rAAVCAGGAD65 and rAAVCAGGFP on feeding and weight gain were compared, showing that GAD65 expression reduces both feeding and weight gain without altering drinking or waste production. Examination of food consumption in the third postoperative week suggests that tolerance to the behavioral impact of GAD gene transfer may occur.
Results
Histological analysis of injection sites revealed robust green fluorescence protein (GFP) gene expression in the region of the LH. The mean volume of hypothalamic tissue transduced by a 500 nl injection of 3 Â 10 10 pt/ml was 0.2570.04 mm 3 . The shape of tissue transduced varied between an ellipsoid and spherical distribution with the long axis oriented in the Z trajectory (Figure 1 Finally, in order to confirm GAD gene transfer, in situ hybridization was performed with probes for the woodchuck post-transcriptional regulatory element (WPRE) sequence in the rAAVCAGGAD65 vector and a negative control probe of identical length constructed to match a viral coding sequence within the Ad5RSVlacZ adenoviral vector. The probes were tested on the control, rAAVCAGGFP-injected brain sections to confirm the coexpression of transgene with specific in situ staining for the WPRE sequence. Next, hypothalamic tissue taken from rAAVCAGGAD65-injected animals was stained with either control probe or the WPRE probe. Figure 2 demonstrates that animals injected with rAAVCAG-GAD65 retain vector sequence in the cells of the LH 21 days after surgery. A separate experiment was designed to compare LH rAAV gene expression at 7, 14, and 21 days (n ¼ 15). The mean number of transduced neurons per section was 40.476.6, 7074.2, and 8178.1 respectively (ANOVA Po0.002). Tukey test revealed significant (Po0.05) differences between 7 and 14 or 21 day groups, but no difference between 14 and 21 day groups. Further, anti-GAD65 immunohistochemistry revealed elevated GAD65 expression within the LH of animals injected unilaterally with rAAVCAGGAD65 at 7, 14, and 21 days (Figure 3) . Together, these experiments demonstrate that gene expression reached a plateau in the LH at 2 weeks, with persistent detectable viral sequence in rAAVCAG-GAD65 animals at the experiment's termination at 3 weeks.
Metabolic data reveals that reduced food intake in animals following rAAVCAGGAD65 diminishes weight gain. Individual treatment groups were balanced with respect to initial weight. Mean weights for the rAAV-CAGGAD65 group, rAAVCAGGFP group, and PBS group were 316, 308, and 311 grams respectively (ANO-VA P ¼ 0.847). The slope in weights over the post- (Figure 4 ). Individual t-tests performed to test individual differences between groups revealed a significant difference between the rAAVCAGGAD65 and rAAVCAGGFP groups (Po0.047), and between the rAAVCAGGAD65 and PBS groups (Po0.005). No difference was detected between the PBS and rAAV-CAGGFP groups. Figure 5 demonstrates that mean daily food consumption in the rAAVCAGGAD65 group fell during the first postoperative week, while it remained stable in both the PBS and GFP groups (ANOVA; Po0.007). Pairwise multiple comparison procedures (Tukey Test) revealed statistically significant differences between the both the GAD group and the PBS and GFP groups, respectively, Hypothalamic rAAVCAGGAD65 gene inhibits feeding AJ Noordmans et al but not between the PBS and GFP groups. Similarly, mean daily food consumption increased in the PBS and GFP groups during the second week, in comparison to persistently suppressed levels in the GAD group (ANOVA; Po0.007). Once again, pairwise multiple comparisons revealed significant differences between the GAD group and the PBS and GFP groups, respectively, but not between the PBS and GFP groups. ANOVA comparing data from the third postoperative week did not reveal a difference between the three groups (ANOVA; P ¼ 0.89). ANOVAs conducted on the difference in pre-and postoperative waste production (P ¼ 0.519) and water consumption (P ¼ 0.923) revealed no significant differences. These measurements suggest that the weight gain differences observed were due to neither increased waste production nor differences in drinking behavior.
Discussion
The present experiment demonstrates that rAAV2 vectors can be used to accurately transduce small deep brain nuclear structures without affecting nearby functionally distinct nuclei. Specifically, microinjection of 500 nl of rAAV2 solution at a titer of 3 Â 10 10 pt/ml causes neuronal gene expression in a 0.25 mm 3 volume. Using standard rat stereotactic technique, gene transfer in the present study targets the LH but does not overlap with the VMH. Further, gene transfer using this vector was sustained at 3 weeks following injection, and elicited no signs of local tissue inflammation. Finally, injection of the vector rAAVCAGGAD65 into the LH resulted in a reduction in the standard daily weight gain observed in Wistar rats compared with PBS-injected controls. Animals injected with rAAVCAGGFP demonstrated no alteration in standard weight gain compared with PBSinjected controls. During the first two postoperative weeks, GAD65 gene expression was associated with reduced food intake in comparison with both GFP and PBS groups. No difference in drinking or waste production could be detected between the groups.
Of the six serotypes of AAV, the application of AAV2 to the nervous system has been studied in the greatest depth. In non-neuronal in vitro systems, AAV2 uptake depends on binding to heparin sulfate proteoglycans on the cell surface. 17 Our own data and that of others suggest that CNS injection of AAV2 has no deleterious effects on tissue. Chamberlin et al 18 were unable to detect microglial infiltrates or gliosis in transgene-expressing tissue. In a series of behavioral experiments, amphetamine caused similar locomotor effects and stereotyped behaviors in rats following AAV versus control substantia nigra injections, demonstrating that AAV gene transfer alone does not alter synaptic function locally. 19 Recently, it has been reported that AAV5 infects cells of the nervous system more efficiently than AAV2. 17 Davidson et al 17 have demonstrated that striatal AAV5 injections transduce a significantly greater number of cells of a wider variety. While AAV2 transduces predominantly neuronal cells, AAV5 has the capacity to transduce both glia and neurons. Finally, AAV5 transduces cells over a broader volume than AAV2. Thus, AAV5 is likely to be a superior vector for delivery of transgenes to glial or to neurons over a broad area. Such Figure 4 Slope of average weight of rats. A postoperative comparison of the slope of weight gain in rats injected with rAAVCAGGAD versus rats injected with placebo and control: weight gain is reduced in rats with LH GAD65 expression in comparison with control vector and PBS-injected animals (Po0.014). Figure 5 Postoperative food consumption. Change in food consumption in comparison with the preoperative baseline is portrayed for postoperative weeks 1, 2, and 3. In the first week, food consumption dropped in the GAD group compared to stable consumption in the GFP and PBS control groups (Po0.007). While food consumption increased in the control groups in week 2, consumption remained depressed in the GAD group (Po0.007).
Food consumption normalized at week 3.
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AJ Noordmans et al delivery may be critical to neurorestorative gene delivery strategies. In contrast, the heparin binding characteristics of the AAV2 capsid 20 are likely to restrict the diffusion of this vector through brain parenchyma. This characteristic lends AAV2 to functional neuromodulation, which depends on focused gene delivery.
The mechanism whereby AAVCAGGAD65 induces LH neuronal inhibition remains unclear. There continues to be a controversy as to whether neurons of the LH or axons passing through the LH are primarily responsible for reduced feeding following LH lesions. Either mechanism might explain the effects of GAD65 gene transfer. Work in our laboratory 21 and others 22, 23 demonstrate that AAV2 vectors undergo retrograde axonal transport following injection into projection areas or fiber bundles. As such, rAAVCAGGAD65 injection into the LH may have its functional effect by altering the phenotype of cells projecting into or through this region. Alternatively, gene transfer to the cells of the LH may have resulted in local inhibition. The fact that bicuculline injection into the LH results in hyperphagia 14 suggests that the increased production of GABA in this region would be capable of inhibiting feeding. However, this hypothesis depends on either a GABAergic autocrine effect or reciprocal inhibition among cells of the LH that produce increased amounts of GABA following GAD65 transduction.
Importantly, reduced food intake persisted in the present experiment for the first two postoperative weeks, but was not detected in the final week of observation. The time course of this behavioral effect was unexpected given that most investigators have observed a slow onset of rAAV gene expression with persistent expression well beyond 3 weeks. Since in situ hybridization demonstrates persistence of the rAAVCAGGAD65 genome at 3 weeks, elimination of the vector DNA can be ruled out. Nonetheless, silencing of gene expression remains a possible explanation for the return to baseline feeding behavior. However, GAD65 overexpression was detected in the LH by anti-GAD65 immunohistochemistry 3 weeks after vector injection. Further, the negative control vector used in the current experiment is identical to the GAD65 vector with the exception of the transgene itself. As the vector coat, promoter, and WPRE sequence are identical, gene expression from the two vectors should parallel each other. Long lasting gene expression by AAV vectors in the mammalian brain has been demonstrated by a variety of investigators. For example, Bankiewicz et al 24 demonstrated persistent activity of L-amino-acid decarboxylase (AADC) in monkey striatum 7-8 weeks after deep brain injection of AAV-AADC. Most compelling, however, is data previously published by the authors. 9 Deep brain nuclei injection of the same vector (rAAVCAGGAD65) was shown with immunohistochemistry for GAD65 to maintain gene expression 4-5 months after injection. More importantly, following STN vector injection, in vivo dialysis revealed increased GABA production and electrophysiology revealed sustained synaptic inhibition. Finally, in this experiment the behavioral impact of GAD expression was sustained. These data derived from the injection of the same vector into an alternative deep brain nuclei make gene silencing an extremely unlikely explanation for the return to baseline feeding behavior observed in the present experiment at 3 weeks.
The behavioral effect of LH GAD expression was observed in the first week after viral injection. Previous studies of the behavioral effects of cerebral transgene expression have noted delayed onset. Sanchez-Pernaute et al 25 documented the initiation of turning behaviors in response to unilateral striatal AAV2-AADC injection at 10 days. The transgene, AADC, functions like GAD to increase the production of a small neurotransmitter. rAAV-induced gene expression is known to begin in the brain within the first week of injection. rAAV2 particles transit from the extracellular space to the nuclei of brain neurons within 30 min. 26 McCown et al 27 noted rAAVdriven transgene expression 1 week after intracerebral vector injection. No difference was found in rAAV2-induced GFP expression driven by the CMV promoter in the globus pallidus between 2 weeks and 1 month. 28 A comparison of rAAV2 vectors containing a variety of promoters driving the luciferase gene has shown gene expression at 2 weeks in brain, with previous experience suggesting increasing expression between 7 and 14 days. 29 To further probe this issue, gene expression following rAAVCAGGFP was tracked at 1, 2, and 3 weeks in the present experiment. Significant gene expression was detected at 1 week with an increase in the second week. No change in gene expression was detected from 2 to 3 weeks. Since the GAD and GFP conditions were identical with respect to vector design, titer, and surgery, it is probable that GAD expression parallels this time course. In addition, anti-GAD65 immunohistochemistry demonstrates GAD65 overexpression in the LH 1 week after injection. The fact that the behavioral effect appears to diminish, at precisely the time point that gene expression plateaus, suggests a synaptic mechanism for a reduction in the behavioral response rather than a gene expression-based mechanism.
Tolerance to chronically elevated agonist levels has been documented for a variety of neurotransmitters including serotonin, 30 opiate, 31 cholinergic, 32 and GABAergic 33 systems. A variety of mechanisms exist for tolerance in these systems ranging from simple receptor downregulation to changes in second messenger systems and more complicated polysynaptic multitransmitter system mechanisms. For example, tolerance within the GABA system may vary depending on whether GABA itself or benzodiazepines are used as the agonist to induce tolerance. 33 Thus, while there is an extensive precedence for neurotransmitter tolerance in peptide and nonpeptide systems, the mechanism at work in the current context bears further investigation. The array of potential mechanisms for tolerance to GABA production suggests the possibility of contrasting mechanisms functioning in different cerebral nuclei. Our laboratory has begun to apply slice electrophysiology to elucidate the mechanism whereby GAD gene transfer induces local inhibition as well as the mechanism for possible tolerance. The present experiment reinforces the utility of gene-based neural inhibition. However, transgenes that target neural transmitter production may be susceptible to synaptic compensation. The introduction of regulated gene expression may allow for reduced tolerance through modulated levels of neurotransmitter production. Alternatively, the introduction of transgenes less susceptible to synaptic plasticity may eliminate the potential for tolerance in gene-based neuromodulation. 
Conclusion
Stereotactic administration of small volumes of AAV2 vectors to deep brain nuclei can deliver transgenes to a focused and accurately targeted volume of brain parenchyma. This accuracy renders focused neuromodulation possible through the delivery of transgenes capable of altering synaptic activity. Delivery of GAD65 to the LH nucleus of Wistar rats, using rAAVCAGGAD65, can induce a reduction in postinjection weight gain through a reduction in feeding behavior without affecting other hypothalamic-driven behaviors.
Methods
Vector design Plasmid construction. The human GAD65 cDNA was inserted into an rAAV backbone containing the CMV enhancer/chicken beta actin promoter (CBA), a WPRE, and the bovine growth hormone polyA (rAAVCAG-GAD65). EGFP (Clontech, Palo Alto, CA, USA) was inserted into the same rAAVCBA-WPRE-bGH backbone (rAAVCAGGFP).
Recombinant AAV production. HEK 293 cells were plated out at a density of 2 Â 10 7 cells per 15 cm dish in DMEM supplemented with 10% fetal bovine serum, 500 U penicillin/streptomycin and 1 Â nonessential amino acids (all from Cellgro, Mediatech Inc., Herndon, VA, USA). Each batch of vector stock was generated from five 15 cm dishes. Cells were transfected with the AAV cis plasmid and pDG (AAV2 helper plasmid) by the standard calcium phosphate method. 34 At 48 h after transfection, the cells were harvested and the virus purified using heparin affinity columns (Sigma) according to the method of Clark et al. 35 The virus was dialyzed against 1 Â PBS and stored at 41C. The genomic titer of each virus was determined quantitatively using the ABI 7700 real-time PCR machine (Applied Biosystems, Foster City, CA, USA). Vector titers were standardized to 3 Â 10 10 genomes/ml. The authors have previously demonstrated that this vector is capable of inducing increased GABA production through GAD65 expression. 9 In these experiments, HPLC was used to demonstrate a 400% increase in GABA production 48 h after exposure to rAAVCAGGAD65 in comparison with rAAVCAGGFP and vehicle. In vivo dialysis was further used to confirm the induction of GABA production by GAD expression in vivo.
9
Vector injection. Standard rat stereotactic technique was used to place a pulled glass micropipette attached to a Nanoject microinjector (Drummond) into the LH. Coordinates used for the LH were previously published (X ¼ 1.8, Y ¼ À2.7, Z ¼ 8.6). The nanoject was used to administer a series of ten 50 nl boluses over 2 min for a total of 0.5 ml. A viral titer of 3 Â 10 10 genomes/ml was utilized in all experiments. Virus was dialyzed into a PBS vehicle solution. Three groups of animals were injected in the LH bilaterally; rAAVCAGGFP (n ¼ 5) or rAAV-CAGGAD65 (n ¼ 5) and PBS controls (n ¼ 5). In a separate experiment, the LH was injected unilaterally with rAAVCAGGFP and animals were killed at 7 (n ¼ 5), 14 (n ¼ 5), and 21 days (n ¼ 5). Finally, three animals received left sided rAAVCAGGFP LH injections and right sided rAAVCAGGAD65 LH injections. These animals were killed at 7, 14, and 21 days respectively. The same titer, volume, and surgical technique were applied in this second experiment.
Tissue analysis Volume of tissue transduced. Brain sections with fluorescence were digitally imaged under Â 10 magnification (Spot camera). Using the same magnification, a micron scale is then imaged. Metamorph image analysis software is used to quantify area based on a known line distance and its conversion from pixels to millimeters. Area measurements are made every 250 mm. The volume of distribution for gene expression is calculated as the mean area multiplied by the length over which staining is detected. Cell counts. Brains taken from the animals that had undergone unilateral rAAVCAGGFP injection were sectioned at 15 mm thickness. Every fifth section was saved. The five sections with maximal fluorescence were digitally imaged (Spot camera), and the total number of GFP-expressing cells per section was quantified using Metamorph image analysis. The mean cells per section was calculated from these five sections.
In situ hybridization
Fluorescent in situ hybridization (FISH) was performed on brain sections from rats that had been peripherally injected with rAAVCAGGFP. A cDNA probe for the WPRE sequence within the AAV vector and the adenoviral intermediate gene IVa2 were constructed. The 591 bp sequence of WPRE was cut from the pAM/ CAG-EGFP-WPRE-BGH polyA plasmid with Cla I and the 587 bp sequence of IVa2 was cut from pAd5IVa2 with Pst I. The individual fragments were subject to gel extraction and purification. DNA fragments were labeled via a nick translation reaction in which 1 mg of DNA was mixed with 0.2 mM SpectrumRed-dUTP (Vysis Inc., Downers Grove, IL, USA), 0.1 mM dTTP, 0.1 mM dNTP mix, and 10 ml of Escherichia coli DNA polymerase I nick translation enzyme (Vysis Inc., Downers Grove, IL, USA). The reaction mixture was centrifuged at 46 K r.p.m. for 30 s, vortexed, and incubated at 151C for 8 h. The labeling reaction was stopped by heating the reaction mixture to 701C for 10 min and chilling on ice. The size of labeled probes was verified on 2% agarose gel.
Frozen sections (15 mm) were brought to room temperature and air dried prior to applying the probe. Probes were suspended in hybridization buffer at a 1:100 dilution. Hybridization buffer contained 5 ml Hypothalamic rAAVCAGGAD65 gene inhibits feeding AJ Noordmans et al deionized formamide, 2 ml 20 Â SSC, 0.2 ml Denhardt's, 0.5 ml salmon sperm DNA (10 mg/ml), 0.25 ml yeast tRNA (10 mg/ml), and 2 ml of 50% dextran sulfate. DNA was denatured at 951C for 10 min immediately before application. Slides were then covered with Hybriwells (Thomas Scientific) and placed in a humidified chamber to prevent dehydration at 371C overnight. The following day, the slides were dipped in 0.1 Â SSC at room temperature twice, followed by 2 Â 15 min rinses in 0.1 Â SSC at 551C, 2 Â 15 min rinses in 0.5 Â SSC at 551C, and a final rinse in 0.5 Â SSC at room temperature for 15 min. The sections were allowed to air dry prior to application of coverslips with Gel/Mount (Biomeda, Foster City, CA, USA). Initially, tissue sections from rAAVCAGGFP control animals were stained with either the WPRE or Adenoviral probe. Confocal microscopy confirmed specific staining of cells expressing the GFP transgene. Next, tissue sections from rAAVCAGGAD65-injected animals were stained with either the WPRE or Ad probes. Fluorescent microscopy was used to confirm the presence of the viral genome in LH.
Immunohistochemistry
Following perfusion with 2% PFA, rat brains were cut in 30 mm sections using a Reichert Jung Frigocut cryostat and visualized for GFP using fluorescent microscopy (Leica Microsystems, Inc. Bannockburn, IL, USA). Sections positive for GFP expression in the left LH were washed with PBS þ triton-X (Sigma Aldrich, St Louis, MO, USA) and 200 ml of monoclonal anti-hGAD65 antibody (1/2000 dilution; Chemicon Temecula, CA, USA) was added to each section. Sections were incubated overnight on an orbital shaker at 30 r.p.m. at 41C. FITCconjugated secondary antibody (200 ml) (1/250 dilution; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was then added to each section, and the sections were incubated for 3 h at room temperature on an orbital shaker at 30 rpm in the dark. The sections were washed with PBS, mounted on coverslips and allowed to dry in the dark before visualization using fluorescent microscopy.
Metabolic measurements. All animals were housed in individual cages. Daily water and rat chow consumption was recorded. Animals were weighed on a daily basis. Animal pine dry was weighed before placement into cages and after removal to gauge the weight of stool and urine.
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